Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

Company Overview

Sonoma Pharmaceuticals, Inc. develops and commercializes non-antibiotic and specialty healthcare products based primarily on its Microcyn technology, which uses stabilized hypochlorous acid solutions. The company’s products are designed to support wound cleansing and management, skin conditions, and other applications where antimicrobial activity and tissue compatibility are important.

Its product portfolio has included solutions and gels marketed for wound care, dermatology, eye care, and veterinary applications. Products have been sold under brands including Microcyn, MicrocynAH, Celacyn, Levicyn, and Lasercyn, although product availability and markets may vary by geography and regulatory approval.

The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Based in Petaluma, California, Sonoma Pharmaceuticals has pursued commercial and distribution relationships in the United States and international markets. Its products have been marketed through healthcare providers, distributors, pharmacies, and animal-health channels.

Key Stats

• Today's Range: $1.22 to $1.29
• 50-Day Range: $1.12 to $1.44
• 52-Week Range: $0.85 to $4.25
• Volume: 8,728 shs
• Average Volume: 121,276 shs
• Market Capitalization: $5.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Sonoma Pharmaceuticals Stock Analysis - MarketRank™

Sonoma Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Sonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Sonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sonoma Pharmaceuticals is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sonoma Pharmaceuticals is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sonoma Pharmaceuticals has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.47% of the float of Sonoma Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sonoma Pharmaceuticals has recently decreased by 18.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sonoma Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Sonoma Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Sonoma Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sonoma Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

4 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.02% of the stock of Sonoma Pharmaceuticals is held by insiders.

Percentage Held by Institutions

1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SNOA
• CIK: 1367083
• Web: www.sonomapharma.com
• Phone: (800) 759-9305
• Fax: 707-283-0551
• Employees: 260
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.17 million
• Net Margins: -10.33%
• Pretax Margin: -11.44%
• Return on Equity: -21.41%
• Return on Assets: -6.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.99
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $19.53 million
• Price / Sales: 0.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 4,790,000
• Free Float: 4,739,000
• Market Cap: $5.91 million
• Optionable: Not Optionable
• Beta: 1.30